Caliway Biopharmaceuticals C, TW0006919004

Caliway Biopharmaceuticals stock advances as Phase 3 expands

Published on 11/03/2026 at 17:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Caliway Biopharmaceuticals stock gains a new clinical milestone as its second global Phase 3 trial begins enrollment. Another Phase 2 study is advancing in Asia-Pacific.

Caliway expands its Phase 3 program

SUPREME-02 has started enrolling patients for a randomized, placebo-controlled study of CBL-514.
The company expects to present combination-therapy data at ObesityWeek 2026 on November 15.
Additional Phase 2 enrollment continues in Taiwan and Australia.

Caliway Biopharmaceuticals C, TW0006919004, Illustration mit AI erstellt.

Caliway Biopharmaceuticals said on October 29, 2026, that enrollment had begun in SUPREME-02, its second global pivotal Phase 3 trial for CBL-514. The company release describes the program as a randomized, double-blind, placebo-controlled study targeting abdominal subcutaneous fat reduction.

The trial is planned to enroll approximately 320 participants at 30 to 35 sites in the United States, Canada and Australia. Caliway said the study will assess efficacy, safety and tolerability through patient and clinician assessments as well as magnetic resonance imaging.

Second pivotal trial broadens development

SUPREME-02 will complement the ongoing SUPREME-01 study. Caliway said the two trials are intended to generate clinical evidence for potential future regulatory submissions for CBL-514, an investigational small-molecule injection designed to reduce subcutaneous fat at the treatment site.

The company is also continuing enrollment in the CBL-0206 Phase 2 study in Taiwan and Australia. Caliway said the regional trial is intended to expand clinical data in Asian populations and support future regulatory, commercialization and partnering plans.

Combination data due in November

Caliway plans to present new preclinical combination-therapy findings at ObesityWeek 2026 in Washington, D.C., on November 15. The presentation will examine CBL-514 alongside the GLP-1 receptor agonist semaglutide and the amylin receptor agonist eloralintide, with a focus on weight reduction and post-treatment weight regain.

The October 29 announcement advances the clinical calendar but does not establish regulatory approval or commercial availability. Investors will therefore continue to focus on enrollment progress, trial execution and the evidence generated by the two pivotal studies.

The broader biotechnology market can be followed in current market reports.

Further developments are available in more news and analyses on Caliway Biopharmaceuticals stock.